{"id":1689,"date":"2026-06-30T06:46:21","date_gmt":"2026-06-30T06:46:21","guid":{"rendered":"https:\/\/www.perspireip.com\/blog\/patent-term-extension-guide\/"},"modified":"2026-06-30T06:46:21","modified_gmt":"2026-06-30T06:46:21","slug":"patent-term-extension-guide","status":"publish","type":"post","link":"https:\/\/www.perspireip.com\/blog\/patent-term-extension-guide\/","title":{"rendered":"Patent Term Extension: 6 Essential Rules"},"content":{"rendered":"\n<div class=\"wp-block-rank-math-toc-block\" id=\"rank-math-toc\"><h2>Table of Contents<\/h2><nav><ul><li class=\"\"><a href=\"#what-a-patent-term-extension-restores\">What a Patent Term Extension Restores<\/a><\/li><li class=\"\"><a href=\"#rule-1-only-fda-regulated-products-quali\">Rule 1: Only FDA-Regulated Products Qualify<\/a><\/li><li class=\"\"><a href=\"#rule-2-file-within-60-days-of-approval\">Rule 2: File Within 60 Days of Approval<\/a><\/li><li class=\"\"><a href=\"#rule-3-and-4-the-5-year-cap-and-the-14-y\">Rule 3 and 4: The 5-Year Cap and the 14-Year Cap<\/a><\/li><li class=\"\"><a href=\"#rule-5-one-patent-per-product\">Rule 5: One Patent Per Product<\/a><\/li><li class=\"\"><a href=\"#rule-6-how-the-extension-is-calculated\">Rule 6: How the Extension Is Calculated<\/a><\/li><li class=\"\"><a href=\"#pte-vs-pta-two-different-clocks\">PTE vs PTA: Two Different Clocks<\/a><\/li><li class=\"\"><a href=\"#what-it-means-for-your-product-strategy\">What It Means for Your Product Strategy<\/a><\/li><li class=\"\"><a href=\"#how-perspireip-can-help\">How PerspireIP Can Help<\/a><ul><li class=\"\"><a href=\"#t1\">How much patent term can an extension add?<\/a><\/li><li class=\"\"><a href=\"#t2\">What is the deadline to apply?<\/a><\/li><li class=\"\"><a href=\"#t3\">How is a patent term extension different from patent term adjustment?<\/a><\/li><li class=\"\"><a href=\"#t4\">Can more than one patent be extended for the same product?<\/a><\/li><li class=\"\"><a href=\"#t5\">Which products are eligible?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n\n\n\n<p>A drug patent can sit largely unused for a decade while the product crawls through FDA review, and by the time it clears, much of the 20-year term is gone. A <strong>patent term extension<\/strong> exists to give some of that time back. Under the Hatch-Waxman Act and 35 U.S.C. 156, the owner of a patent covering an FDA-regulated product can recover up to five years lost to regulatory review\u2014but only if six fairly unforgiving rules are met. Here is how the system works and where applicants lose the right.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"what-a-patent-term-extension-restores\">What a Patent Term Extension Restores<\/h2>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1200\" height=\"675\" src=\"https:\/\/www.perspireip.com\/blog\/wp-content\/uploads\/patent-term-extension-guide-fig1.jpg\" alt=\"Patent term extension under the Hatch-Waxman Act for regulated products\" class=\"wp-image-1687\" srcset=\"https:\/\/www.perspireip.com\/blog\/wp-content\/uploads\/patent-term-extension-guide-fig1.jpg 1200w, https:\/\/www.perspireip.com\/blog\/wp-content\/uploads\/patent-term-extension-guide-fig1-300x169.jpg 300w, https:\/\/www.perspireip.com\/blog\/wp-content\/uploads\/patent-term-extension-guide-fig1-1024x576.jpg 1024w, https:\/\/www.perspireip.com\/blog\/wp-content\/uploads\/patent-term-extension-guide-fig1-768x432.jpg 768w\" sizes=\"auto, (max-width: 1200px) 100vw, 1200px\" \/><figcaption class=\"wp-element-caption\">Photo: <a href=\"https:\/\/commons.wikimedia.org\/w\/index.php?curid=119997838\" rel=\"nofollow noopener\" target=\"_blank\">NanningTianchiShanPharmacy<\/a> by F\u00e9lix An (<a href=\"https:\/\/creativecommons.org\/licenses\/by\/4.0\/\" rel=\"nofollow noopener\" target=\"_blank\">CC BY 4.0<\/a>)<\/figcaption><\/figure>\n\n\n\n<p>A <strong>patent term extension<\/strong> (PTE) compensates a patent owner for time the patented product could not be sold because it was awaiting federal regulatory approval. It was created by the 1984 Drug Price Competition and Patent Term Restoration Act\u2014the Hatch-Waxman Act\u2014and codified at 35 U.S.C. 156.<\/p>\n\n\n\n<p>The logic is straightforward. A patent&#8217;s clock starts at filing, but a new drug cannot reach the market until the FDA clears it years later. PTE returns part of that lost time so the patent delivers something closer to its intended commercial life. For a blockbuster therapy, each restored month can be worth a great deal, which is why this corner of patent law gets so much attention from life-sciences companies and their investors.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"rule-1-only-fda-regulated-products-quali\">Rule 1: Only FDA-Regulated Products Qualify<\/h2>\n\n\n\n<p>Restoration is not available to patents generally. The patent must claim a product\u2014or a method of using or manufacturing it\u2014that was subject to a defined regulatory review period before it could be marketed. The qualifying categories are spelled out in the statute:<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>Human drugs, antibiotics, and biologics<\/li><li>Medical devices requiring premarket approval<\/li><li>New animal drugs and veterinary biologics<\/li><li>Food additives and color additives<\/li><\/ul>\n\n\n\n<p>Software, mechanical inventions, and most consumer products never touch this regime\u2014their term is what it is. The extension is a creature of the FDA approval pipeline, so the first question is always whether the product ran a genuine regulatory gauntlet, not merely a voluntary one.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"rule-2-file-within-60-days-of-approval\">Rule 2: File Within 60 Days of Approval<\/h2>\n\n\n\n<p>The single deadline that sinks the most applications is the filing window. Under 35 U.S.C. 156(d)(1), the application must be filed within the 60-day period beginning on the date the product receives FDA permission for commercial marketing or use.<\/p>\n\n\n\n<p>Sixty days is short, the clock is jurisdictional, and there is no informal grace period. Miss it and the right is gone, no matter how strong the underlying patent. The application goes to the USPTO\u2014whose <a href=\"https:\/\/www.uspto.gov\/patents\/laws\/patent-terms-extended\" rel=\"noopener\" target=\"_blank\">patent term extension resources<\/a> set out the procedure\u2014which then coordinates with the FDA on the eligible review period. Because approval dates can slip and then suddenly land, the practical move is to have the paperwork drafted before the FDA decision, not after.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"rule-3-and-4-the-5-year-cap-and-the-14-y\">Rule 3 and 4: The 5-Year Cap and the 14-Year Cap<\/h2>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1200\" height=\"675\" src=\"https:\/\/www.perspireip.com\/blog\/wp-content\/uploads\/patent-term-extension-guide-fig2.jpg\" alt=\"Patent term extension five-year cap and fourteen-year post-approval limit\" class=\"wp-image-1688\" srcset=\"https:\/\/www.perspireip.com\/blog\/wp-content\/uploads\/patent-term-extension-guide-fig2.jpg 1200w, https:\/\/www.perspireip.com\/blog\/wp-content\/uploads\/patent-term-extension-guide-fig2-300x169.jpg 300w, https:\/\/www.perspireip.com\/blog\/wp-content\/uploads\/patent-term-extension-guide-fig2-1024x576.jpg 1024w, https:\/\/www.perspireip.com\/blog\/wp-content\/uploads\/patent-term-extension-guide-fig2-768x432.jpg 768w\" sizes=\"auto, (max-width: 1200px) 100vw, 1200px\" \/><figcaption class=\"wp-element-caption\">Photo: <a href=\"https:\/\/commons.wikimedia.org\/w\/index.php?curid=2787829\" rel=\"nofollow noopener\" target=\"_blank\">File:Benz Patent Motorwagen Engine.jpg<\/a> by LSDSL (<a href=\"https:\/\/creativecommons.org\/licenses\/by-sa\/2.0\/de\/deed.en\" rel=\"nofollow noopener\" target=\"_blank\">CC BY-SA 2.0<\/a>)<\/figcaption><\/figure>\n\n\n\n<p>Two ceilings limit how much time you can recover. First, the extension cannot exceed five years. Second, the total remaining term\u2014measured from the product&#8217;s approval date\u2014cannot exceed 14 years once the extension is added.<\/p>\n\n\n\n<p>So a patent that already has 11 years left after approval can be extended by at most three years, not five. The 14-year cap, at 35 U.S.C. 156(c)(3), often bites harder than the five-year limit, and it should be modeled early when valuing a pharmaceutical patent or pricing a licensing deal. Two products with identical review delays can end up with very different restored terms purely because their patents issued at different points in development.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"rule-5-one-patent-per-product\">Rule 5: One Patent Per Product<\/h2>\n\n\n\n<p>A product may be covered by a patent thicket\u2014composition of matter, formulation, method of treatment\u2014but only one patent can be restored for a single regulatory review period under 35 U.S.C. 156(c)(4). Choosing which patent to extend is a strategic decision that should weigh remaining term, claim scope, and likely generic challenges, not just the expiry date on each.<\/p>\n\n\n\n<p>Pick the patent that protects the franchise the longest and the most defensibly. A composition-of-matter claim is usually harder for a generic to design around than a narrow formulation claim, so the patent with the latest expiry is not always the smartest election. Once you choose, you generally cannot move the benefit to a sibling patent later, so the decision rewards careful analysis up front.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"rule-6-how-the-extension-is-calculated\">Rule 6: How the Extension Is Calculated<\/h2>\n\n\n\n<p>The eligible regulatory review period has two parts: the testing phase, from the effective date of the investigational exemption (the IND) to the submission of the marketing application, and the approval phase, from that submission to final FDA approval.<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>Only one-half of the testing (IND) phase counts toward the restored time.<\/li><li>The entire approval (NDA or BLA review) phase counts.<\/li><li>Any period in which the applicant did not act with due diligence is subtracted.<\/li><li>The result is then trimmed to fit the 5-year and 14-year caps.<\/li><\/ul>\n\n\n\n<p>Because only half the testing phase counts but all of the approval phase does, delays late in the process tend to be more recoverable than early ones. Modeling the calculation while a product is still in trials, rather than after approval, lets a company see how much term is actually at stake and document the diligence it will later need to prove.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"pte-vs-pta-two-different-clocks\">PTE vs PTA: Two Different Clocks<\/h2>\n\n\n\n<p>This is where restoration differs sharply from patent term adjustment. PTA, under 35 U.S.C. 154(b), compensates for USPTO delay during prosecution; the Hatch-Waxman remedy compensates for FDA delay after the patent issues. The two are separate, governed by different statutes, and can be stacked on the same patent\u2014our explainer on <a href=\"https:\/\/www.perspireip.com\/blog\/patent-term-adjustment-and-extension\">patent term adjustment and extension<\/a> walks through how they interact.<\/p>\n\n\n\n<p>In practice you treat them as two independent levers on the back end of a patent. PTA is calculated automatically at grant from the prosecution record; the FDA-based remedy must be applied for, on a deadline, with supporting data. A strong portfolio plan accounts for both rather than assuming one covers the other.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"what-it-means-for-your-product-strategy\">What It Means for Your Product Strategy<\/h2>\n\n\n\n<p>For a life-sciences company, the back end of a patent is often where the money is. The years restored here are the years a product enjoys without generic or biosimilar competition, and they typically fall at the most profitable point in the product&#8217;s life. That makes this remedy a board-level issue, not just a prosecution detail.<\/p>\n\n\n\n<p>The companies that capture the most value tend to do three things early. They identify, during clinical development, which patent they would elect to restore. They build a diligence record that withstands later scrutiny of the review period. And they diary the 60-day deadline against the projected approval date so the filing is ready the moment the FDA acts. Treating the calculation as something to figure out after approval is exactly how recoverable years get left on the table.<\/p>\n\n\n\n<p>It is also worth coordinating the analysis with foreign rights. Many jurisdictions offer their own restoration mechanisms\u2014supplementary protection certificates in Europe, for example\u2014each with its own rules and deadlines. The US filing is one piece of a global term-management plan, and the strongest strategies line up all of those clocks at once.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"how-perspireip-can-help\">How PerspireIP Can Help<\/h2>\n\n\n\n<p>For a drug or device franchise, a single well-chosen extension can be worth more than the rest of the portfolio combined\u2014and the 60-day window leaves no room for error. We model the eligible review period, the five- and 14-year caps, and the one-patent election, then prepare and track the application end to end. <a href=\"https:\/\/www.perspireip.com\/contact\">Contact PerspireIP<\/a> to protect the back end of your patent term.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"faq\">Frequently Asked Questions<\/h2>\n\n\n<div id=\"rank-math-faq\" class=\"rank-math-block\">\n<div class=\"rank-math-list \">\n<div id=\"t1\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question \">How much patent term can an extension add?<\/h3>\n<div class=\"rank-math-answer \">\n\n<p>Up to five years, but never enough to leave more than 14 years of term measured from the product&#8217;s FDA approval date. The shorter of the two limits controls.<\/p>\n\n<\/div>\n<\/div>\n<div id=\"t2\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question \">What is the deadline to apply?<\/h3>\n<div class=\"rank-math-answer \">\n\n<p>Within 60 days of the date the product receives FDA permission for commercial marketing or use, under 35 U.S.C. 156(d)(1). The deadline is strict and cannot be waived informally.<\/p>\n\n<\/div>\n<\/div>\n<div id=\"t3\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question \">How is a patent term extension different from patent term adjustment?<\/h3>\n<div class=\"rank-math-answer \">\n\n<p>An extension under 35 USC 156 compensates for FDA regulatory delay; patent term adjustment under 35 USC 154(b) compensates for USPTO prosecution delay. They are separate and can be combined.<\/p>\n\n<\/div>\n<\/div>\n<div id=\"t4\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question \">Can more than one patent be extended for the same product?<\/h3>\n<div class=\"rank-math-answer \">\n\n<p>No. Only one patent can be restored for a single regulatory review period, so owners must choose the most valuable patent to extend.<\/p>\n\n<\/div>\n<\/div>\n<div id=\"t5\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question \">Which products are eligible?<\/h3>\n<div class=\"rank-math-answer \">\n\n<p>Patents claiming FDA-regulated products such as human drugs, biologics, medical devices, new animal drugs, and food or color additives, or methods of using or making them.<\/p>\n\n<\/div>\n<\/div>\n<\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>A patent term extension under 35 USC 156 can restore years a drug or device patent lost during FDA review. Here are the six rules that govern it.<\/p>\n","protected":false},"author":2,"featured_media":1690,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[58],"tags":[367,366,63,365,317],"class_list":["post-1689","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-patent","tag-35-usc-156","tag-hatch-waxman","tag-patent-prosecution","tag-patent-term-extension","tag-pharmaceutical-patents"],"_links":{"self":[{"href":"https:\/\/www.perspireip.com\/blog\/wp-json\/wp\/v2\/posts\/1689","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.perspireip.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.perspireip.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.perspireip.com\/blog\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.perspireip.com\/blog\/wp-json\/wp\/v2\/comments?post=1689"}],"version-history":[{"count":0,"href":"https:\/\/www.perspireip.com\/blog\/wp-json\/wp\/v2\/posts\/1689\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.perspireip.com\/blog\/wp-json\/wp\/v2\/media\/1690"}],"wp:attachment":[{"href":"https:\/\/www.perspireip.com\/blog\/wp-json\/wp\/v2\/media?parent=1689"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.perspireip.com\/blog\/wp-json\/wp\/v2\/categories?post=1689"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.perspireip.com\/blog\/wp-json\/wp\/v2\/tags?post=1689"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}